A liver cirrhosis diagnosis is understandably unsettling, since the liver’s role in the body is so central, and the condition is generally considered a long-term, progressive one. This page explains how cirrhosis is diagnosed, what standard hepatology-led care involves in Malaysia, and what current stem cell research can and cannot show, so you have a clear, honest picture before requesting an assessment.
Liver Cirrhosis Symptoms and Diagnosis
Cirrhosis often develops silently over years, frequently caused by chronic viral hepatitis, long-term alcohol use, or metabolic liver disease. Early stages (compensated cirrhosis) may have few or no symptoms, while later stages (decompensated cirrhosis) bring more noticeable complications.
| Stage | Typical Presentation |
| Compensated cirrhosis | Often asymptomatic; may be found incidentally through blood tests or imaging |
| Decompensated cirrhosis | Jaundice, fluid retention (ascites), confusion (hepatic encephalopathy), bleeding tendencies, significant fatigue |
Diagnosis typically involves:
- Blood tests, including liver function tests, clotting profile, and markers of liver synthetic function
- Imaging, such as ultrasound, FibroScan (transient elastography), or CT/MRI to assess liver structure and scarring
- Liver biopsy, in select cases, to confirm diagnosis or stage severity
- Identifying the underlying cause, such as viral hepatitis B or C, alcohol-related liver disease, or metabolic dysfunction-associated disease
- Severity scoring, using systems such as Child-Pugh or MELD score to guide prognosis and treatment planning
Standard Care for Liver Cirrhosis
Hepatology-led management remains the foundation of cirrhosis care in Malaysia, focused on treating the underlying cause, managing complications, and monitoring for progression.
| Approach | Purpose |
| Treating the underlying cause | Antiviral therapy for hepatitis B/C, alcohol cessation support, metabolic risk management |
| Managing complications | Diuretics for ascites, treatment for encephalopathy, addressing variceal bleeding risk |
| Nutritional support | Protein and dietary guidance, often with input from a dietitian |
| Regular surveillance | Routine imaging and blood tests to monitor liver function and screen for complications |
| Vaccination | Hepatitis A and B vaccination where appropriate, to prevent further liver insult |
| Liver transplant evaluation | For advanced, decompensated cirrhosis where transplant becomes the definitive treatment option |
This hepatology pathway remains the evidence-based standard of care, and anything discussed regarding stem cell therapy should be understood as a potential complement to, not a replacement for, this pathway.
What Current Research Can and Cannot Show about Liver Cirrhosis
Mesenchymal stem cell research in liver disease, including cirrhosis, is an active area of investigation, with growing but still early-stage clinical evidence.
What current research suggests:
- Preclinical and early clinical studies have explored MSC administration for its potential anti-inflammatory and tissue-support effects in liver disease
- Some early-phase human trials have reported improvements in certain liver function markers in selected patient groups
- Researchers are particularly interested in paracrine signalling effects, cells releasing factors that may support a healthier liver environment, rather than directly regenerating large volumes of liver tissue
What current evidence does not establish:
- No regulatory authority has approved stem cell therapy as a treatment that reverses cirrhosis or restores normal liver architecture
- Stem cell therapy has not been shown to prevent the development of liver cancer (hepatocellular carcinoma), which remains a recognised risk in cirrhotic patients regardless of other treatment
- Most human studies remain small, early-phase, and variable in design, making firm conclusions about clinical benefit premature
- Long-term outcome and survival data specific to MSC therapy in cirrhosis remains limited
At 23C Regen, discussions about liver cirrhosis are grounded in this evidence picture. We do not claim our treatment prevents liver cancer or reverses established cirrhosis. An assessment is about reviewing your specific liver function and disease stage honestly.
Liver Cirrhosis Assessment Risks and Exclusions
General risks associated with MSC administration can include:
- Infusion-related reactions
- Rare allergic or immune responses
- Added caution required given the liver’s reduced clotting and metabolic reserve in cirrhotic patients
Patients who may be excluded from assessment or treatment can include those with:
- Decompensated cirrhosis with active, unmanaged complications (such as uncontrolled ascites, active bleeding, or encephalopathy)
- Confirmed or suspected hepatocellular carcinoma, pending oncology evaluation
- Active, untreated infection
- Significant, uncontrolled coagulopathy
- Pregnancy
Suitability depends heavily on your current liver function and disease stage, which is why a documented assessment, not a general conversation, is required before any decision.
Liver Cirrhosis Assessment Records You’ll Need
- Recent liver function test results
- Imaging reports, such as ultrasound, FibroScan, or CT/MRI
- Hepatologist’s notes, including Child-Pugh or MELD score if available
- Information on underlying cause (viral hepatitis status, alcohol history, metabolic risk factors)
- Current medications, particularly any anticoagulants
- Recent cancer screening results, if performed, given the importance of ruling out hepatocellular carcinoma
If some of these aren’t available, our team can advise what’s needed before your assessment.
Liver CirrhosisFollow-Up
Cirrhosis requires ongoing, lifelong monitoring regardless of treatment path. Our approach includes:
- A clear explanation of your liver’s current status following assessment
- Honest guidance on whether stem cell therapy is reasonable to discuss further for your specific stage
- Coordination notes you can share with your treating hepatologist
- Scheduled review points if you proceed with treatment, alongside continued standard surveillance for complications and cancer risk
Questions to Discuss During Your Liver Cirrhosis Assessment
- What stage is my cirrhosis at, and what does that mean for my options?
- What does current evidence actually show for someone at my specific stage?
- Will this affect my ongoing need for liver cancer screening?
- How does this fit alongside my current hepatology care?
- What are the specific risks given my liver’s current function?
- What realistic outcome, if any, should I expect?
Understanding Your Cirrhosis Stage Before Your Assessment
Your Child-Pugh class or MELD score, if you’ve already been evaluated by a hepatologist, gives a useful indication of where your liver function currently stands and what range of options is realistically worth discussing.
| Classification | General Meaning | Typical Focus |
| Child-Pugh A (compensated) | Relatively preserved liver function | Monitoring, treating underlying cause, cancer screening |
| Child-Pugh B | Moderate impairment | Closer monitoring, management of early complications |
| Child-Pugh C (decompensated) | Significant impairment, higher complication risk | Active management of complications, transplant evaluation |
If you don’t yet have this classification, it’s something your hepatologist can determine, and it will meaningfully shape the conversation during any assessment here.
Why a Documented Liver Cirrhosis Assessment Matters More Than a General Opinion
Cirrhosis management decisions carry real weight, given the liver’s central role in clotting, metabolism, and overall health. A general conversation about symptoms, without reviewing your actual liver function tests, imaging, and disease stage, cannot responsibly determine whether any treatment, including stem cell therapy, is appropriate to discuss further. This is precisely why we ask for documented records before any specific recommendation, it protects you from decisions made on incomplete information.
Frequently Asked Questions
Can stem cell therapy reverse liver cirrhosis?
No. Current research does not establish that stem cell therapy reverses cirrhosis or restores normal liver structure once significant scarring has occurred.
Does this treatment prevent liver cancer?
No. There is no evidence that stem cell therapy prevents hepatocellular carcinoma. Regular cancer screening remains essential for all cirrhotic patients regardless of treatment.
Will this replace my current hepatology care?
No. Any assessment at 23C Regen is intended to complement, not replace, your existing hepatologist-led monitoring and treatment plan.
Is this suitable for advanced, decompensated cirrhosis?
Not always. Active complications like uncontrolled ascites or bleeding typically need to be medically stabilised first, and suitability is assessed individually.
What type of stem cells are used for liver conditions?
We use laboratory-cultured Wharton’s Jelly-derived mesenchymal stem cells. Your doctor will explain the specific protocol considered for your case during assessment.
Do I need a hepatologist’s referral before booking?
A referral isn’t required, but bringing your hepatologist’s notes and recent test results helps us provide a more accurate, informed assessment.
Request a Liver Health Assessment
If you’d like an honest, evidence-based conversation about your cirrhosis and what current research can and cannot offer, request an assessment. Review our full list of treatable conditions, learn more about our stem cell therapy, or check pricing beforehand.